CellaVision AB (publ), which develops and sells digital morphology
products for the routine analysis of blood and other body fluids,
presents their new analyzer CellaVision® DM1200 at the international
lab exposition AACC Annual Meeting & Clinical Lab Expo in Chicago,
USA, on July 19-23. The product is commercially available in Europe
and will be available in North America and Japan when CellaVision has
received clearance from the respective countries' authorities.
"We see a substantial potential for this product on the European and
North American markets as trends indicate that not only the large but
also the medium-sized laboratories aim to streamline their analytical
flow," says Yvonne Mårtensson, CEO of CellaVision. "This analyzer is
powerful and flexible, and is intended to serve as a platform for
future applications, giving CellaVision yet more of a competitive
edge."
The CellaVision DM1200 replaces manual microscopy for analysis of
blood samples and is aimed at clinical chemistry laboratories wishing
to automate their manual differentials, making their analytical flow
more efficient. The hardware is prepared for body fluid analysis.
The blood application is included in the CellaVision DM1200 and will
be commercially available in Europe by the end of July. The
application for body fluids is sold as a separate product and is
intended to be released by the end of the year. The company is
planning to apply for product registrations in Canada, the US and
Japan.
CellaVision's current range of products includes the analyzers
CellaVision® DM96 and CellaVision® DM8 as well as software for remote
access, and proficiency testing and education - CellaVision® Remote
Review Software and CellaVision® Competency Software. All of the
products are compatible with each other and can be part of the same
hospital network.
CellaVision DM1200 will be presented at the AACC in Chicago, USA, on
the 19-23 of July 2009 in CellaVision's and Sysmex Amercia's show
cases (238 and 2025 respectively). The convention is expected to draw
20,000 international visitors. For more details, please visit
www.aacc.org.
For more product information and a product picture, please see
below.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision AB develops, markets, and sells market leading image
analysis based systems for routine analysis of blood and other body
fluids. The company has a core competence in development of software
and hardware for automatic image analysis of cells and cell changes
for applications in health and medical care. The company develops and
markets systems for automatic differentials of white blood cells and
red morphology, and software for education and quality assurance of
differentials. The company's associates have expertise in advanced
imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has
subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan.
For more information, visit www.cellavision.com.
CellaVision's share is listed on First North Premier at the OMX
Stockholm Stock Exchange. CellaVision is traded under the ticker
symbol CEVI and the ISIN code SE0000683484. The company's Certified
Advisor is Remium AB.
Features and Benefits - CellaVision® DM1200
CellaVision DM1200 automates the work that is traditionally done by
laboratory personnel using microscopes. The analyzer performs a
preliminary WBC Differential and RBC Characterization, and provides
functionality for platelet estimation. Using technology for digital
image analysis, cells in blood can be classified automatically, which
allows for both time reductions and more standardized analyses. The
Medical Technologist performs the final verification on his or her
computer screen. After signing off the result, it is automatically
sent to the laboratory data system (LIS), where it is archived
together with the patient record. The digital form of the analysis
result provides other benefits, such as traceability and the ability
to share results with colleagues within or outside the hospital,
which increases sharing of expertise between units and makes them
more productive and cost-effective.
CellaVision DM1200 is used after the cell counter has analyzed the
sample and is compatible with all other CellaVision products. It can
easily be a part of any hematology workflow.
Features
* Analysis of Peripheral Blood
* Prepared for Body Fluids
* Allows Digital Slides creation. Primarily for hematology
smears, but also applicable to other types of specimens, such as
Pathology, Cytology and Bone Marrow for research and educational
purposes.
* Automated workflow - walk away
* Sample identification through barcode scanning and LIS
query
* Automatic immersion oil dispensing
* Identification of the optimal analysis area
* WBC Differential
* RBC Characterization
* Pre-classification of blood cells into 18 classes
(WBCs: 12, Non-WBCs: 6)
* Functionality for platelet estimation (PLT)
* Loading capacity: 12 slides
* Throughput: 20 slides/h (peripheral blood)
* Slide preparation methods (wedged): Automated slide maker
and stainers or manual methods. Slides with clipped/round corners.
* Digital archiving of cell images and results together with
the patient record.
